1. Motilal Oswal Financial Services:

This financial services firm rose over 8% on Thursday after its asset management subsidiary reported that its Assets Under Management (AUM) had surpassed Rs 1.5 lakh crore. This marks a sharp increase from a quarter ago, when it was just above Rs 1.2 lakh crore. Over the past five years, its AUM has increased at a CAGR of 34%.

For FY25, the company reported an 18.5% increase in revenue, beating Forecaster estimates slightly by 0.7%. Net profit was flat for the year, mainly due to a Rs 743 crore loss in the treasury segment during Q4, which caused a 15% miss in profit estimates.

Wealth and asset management now contributes over 80% of group revenue, and the remainder comes from the broking and housing finance businesses. Housing finance grew by 13% in FY25, while other verticals saw 30%+ growth. Private Wealth Management remains the most profitable division, contributing more than 40% to operating income.

Group Managing Director, Navin Agarwal, said, “We believe the Private Wealth Management business will contribute a larger share of profitability for the group in the coming years due to higher growth as we continue to penetrate more customers with differentiated products and services.”

Agarwal added, “We believe that the Motilal Oswal Group is very well placed to benefit from the financialization theme, which is a long-term mega trend.” He expects this trend to play out over several decades, especially in India, given the low penetration of investment products and services.

Emkay Global maintains its ‘Buy’ rating on the stock with a lower target price of Rs 850, due to the treasury impact. Despite this, the brokerage expects revenue to grow at a CAGR of 10% and operating profit at a CAGR of 12% over FY26–28, citing the company’s historical resilience in volatile market conditions.

2. Torrent Pharmaceuticals:

This pharma company has risen by 4.5% over the past week after it signed an agreement to buy a controlling stake in JB Chemicals & Pharmaceuticals (JBCP) at a valuation of Rs 25,600 crore. The acquisition will be followed by a merger of the two entities. Torrent Pharma will acquire a 46.4% stake from US-based private equity firm KKR for Rs 11,900 crore, and will later launch a mandatory open offer to acquire up to 26% from public shareholders.

JBCP has reported sales and net profit CAGR of 17% and 19%, respectively over FY22–25, reaching Rs 3,900 crore in revenue and Rs 660 crore in profit. While cardiology is the leading therapy area for both JBCP and Torrent, their focus products differ, which could support complementary growth post-acquisition. Torrent’s market share in cardiology after the acquisition is projected to increase by 410 bps to 11.3%. However, analysts expect the contribution of the India business to Torrent’s overall revenue to rise by only 50 bps, to around 57%. In the international market, there is no overlap for the companies in the US business. In Russia, JB’s brands have been growing at a relatively faster pace, and it also has an established presence in South Africa.

Torrent will get access to JBCP’s international contract development and manufacturing organization (CDMO) business, a segment where it currently has no presence. JBCP leads globally in the lozenges CDMO segment—an oral treatment used to treat throat irritation, which has been a key driver of its international operations.

As of FY25, Torrent has an EBITDA margin of 32%, while JB Pharma’s stands at 26%. Commenting on the potential improvement, Aman Mehta, Whole-time Director, said, “The immediate 1–2 years could see gains in the cost side, through procurement savings, operational efficiencies, and elimination of overlaps. Revenue-side benefits like cross-selling and portfolio expansion should be visible in the following years.” He added that margins should improve over the 3–5 year period, with near-term gains largely driven by cost synergies.

ICICI Securities has a ‘Hold’ rating on Torrent with a target price of Rs 3,500. The brokerage highlights that JB Pharma’s ophthalmology (eye-care) brand could support overall margin expansion post-acquisition. Additionally, the deal may give Torrent an entry into contract manufacturing of lozenges and help strengthen its presence in the US, Russia, and South Africa.

3. Amber Enterprises India:

This consumer electronics company rose by 8.3% over the past week as its subsidiary, IL JIN Electronics entered into a definitive agreement to take a majority stake in Power-One Micro Systems, a battery storage and solar inverter manufacturer. The company’s Executive Chairman & CEO, Jasbir Singh, said, “This transaction will provide a foothold for Amber’s Electronic Division into the rapidly growing sector for batteries, EV chargers, UPS and the solar inverter market.

The company also laid out plans to invest Rs 6,000 crore in an electronics manufacturing plant near Noida International Airport at Jewar. The facility will produce printed circuit boards (PCBs), home appliances, and consumer electronics. Yamuna Expressway Industrial Development Authority (YEIDA) has already issued a Letter of Intent to the firm for 100 acres of land in Noida, near the Yamuna Expressway.

The company posted a 48.1% increase in revenue for FY25, while its net profit surged by 83.3% due to robust growth in consumer durables & electronics segment. It surpassed the Forecaster operating revenue estimate by 4.4%, but missed the net profit estimate by 6.2% as its railway sub-systems & mobility division saw a decline in revenues as the focus remained on non-AC coaches and due to delay in railway projects across regions. The company appears in a screener of stocks with strong momentum.

Mr. Singh, speaking on future guidance, said, “We expect the electronics business to grow by 30% in FY26, with segment PBT margins improving by 300 basis points to 9-10%.” The firm plans to invest Rs 3,000 crore in the electronics segment over the next five years. Of this, 65% of the capex is expected to be recovered through the PLI scheme and government subsidies, while the company will bear the remaining 35%.

Sharekhan has retained a ‘Buy’ rating on Amber Enterprises with a target price of Rs 8,142. The brokerage sees it well positioned to benefit from growing demand in the components ecosystem. It highlights long term growth drivers for the room air conditioner (RAC) industry, including low penetration, rising temperatures, changing lifestyles, and increasing demand from Tier II to Tier IV cities, all of which are expected to boost AC component demand and support Amber’s growth.

4. Apollo Hospitals Enterprise:

This hospital company rose 3.5% on July 1 after announcing the demerger of its non-hospital businesses into a new company, Apollo Healthtech, which is expected to list on stock exchanges within 18 to 21 months.

The demerger consolidates Apollo’s existing pharmacy distribution business (offline and online), Keimed (third-party distribution), and telehealth into a single entity. Post-demerger, Apollo Hospitals will operate two separately listed businesses: one focused on healthcare services (hospitals, diagnostics, and primary/specialty care), and the other on omnichannel pharmacy and digital health through Apollo Healthtech.

In FY25, the businesses proposed for demerger generated revenue of Rs 16,300 crore and aim to reach Rs 25,000 crore by March 2027, with a 7% EBITDA margin. Growth is expected to come from an expanded digital health offering and wider pharmacy reach.

Commenting on Apollo Healthtech's outlook, Madhivanan Balakrishnan, CEO of Apollo Health Co, said, “We are looking at a revenue growth of around 22–23% on a YoY basis. We remain committed to achieving a break-even on the digital Apollo 24/7 platform by the end of this financial year.” Sanjeev Gupta, CFO of Apollo Health added that Apollo 24/7 posted a loss of Rs 80 crore in the last quarter, which is expected to reduce to zero over the next four quarters. The loss was due to the high operating costs associated with scaling its digital healthcare platform.

Analysts believe that the listing of Apollo Healthtech will simplify Apollo’s overall structure and help investors see the value of each business separately. Meanwhile, Apollo Hospitals will focus on core hospital operations as they plan to invest over Rs 8,000 crore in the next five years to add more than 4,300 beds across India. 

Apollo Healthtech will pay a royalty to Apollo Hospitals for the ‘Apollo’ brand name. This royalty is likely to be approximately Rs 10 crore annually, with an increase over time.

Following the announcement, Motilal Oswal reiterated its ‘Buy’ rating with an upgraded target price of Rs 8,720, citing the strategic demerger as a key catalyst. The move unlocks value, enables focused growth, and positions Apollo Healthtech as a leading digital health and pharmacy platform.

5. Gabriel India:

This auto parts & equipment manufacturer rose 44.2% over the past week and touched a 52-week high of Rs 1,011.4 on July 2, after its board announced a restructuring plan. Gabriel's parent company, the ANAND Group, plans to combine and restructure its businesses to achieve revenues of Rs 50,000 crore by 2030.

Gabriel India manufactures suspension parts for two-wheelers, passenger cars, commercial vehicles, and railways. Its parent company, ANAND Group, owns two other automobile-related businesses, Anchemco and Asia Investment. 

Anchemco manufactures vehicle brake fluids, coolants, and diesel exhaust fluids. Asia Investments, along with its joint ventures (JVs), manufactures driveshafts, sealants and sunroofs.

The merger plans involve the restructuring of these two businesses under one roof. Anchemco will merge with Asia Investments. Post merger, the entire automotive business of Asia Investments, including Anchemco and its joint ventures, will be separated and merged into Gabriel.

Alongside this merger, Gabriel is diversifying beyond suspension products into new areas, such as solar dampers for the renewable energy sector. Atul Jaggi, Managing Director, said, “We aim to scale new products like solar dampers to Rs 200-300 crore in revenue over the next 2-3 years. We plan to double sunroof production capacity in the second half of FY26 and intend to expand the product portfolio.”

The company’s net profit rose 14.4% to Rs 211.9 crore in FY25. Revenue grew 8.9% to Rs 3,643.3 crore, driven by higher sales in the two-wheeler segment and the utility vehicles (UVs) segment. Anchemco and its joint ventures generated annual revenue of Rs 4,000 crore in FY26. Post merger, Gabriel's revenue is expected to increase to Rs 8,000 crore.

Elara Securities maintains its 'Buy' rating with a higher target price of Rs 1,115 per share, citing that the company’s transition from a single-product to a multi-product business is expected to improve margins. The brokerage believes that after the merger, the company will expand into multiple products, segments, and geographies. It projects EPS to grow at a 45% CAGR from FY25-27.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations